Study of the Efficacy and Safety of MEDI4893

• Status: Completed
• Trial end date: 2018-10-02
• Target enrollment: 0
• Participant gender: All

Summary

Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MedImmune LLC
• Collaborators: Antibacterial Resistance Leadership Group; Innovative Medicines Initiative and COMBACTE-NET; National Institute of Allergy and Infectious Diseases (NIAID)

Criteria

Inclusion Criteria:

• Colonized with Staphylococcus aureus, expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia.

Exclusion Criteria:

• Staphylococcal disease at randomisation; lung injury score consistent with pneumonia; current lung disease; chronic tracheostomy patients; currently receiving systemic anti-staphylococcal antibiotics; moribund patients.